RAAV9-CB6-AspA ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 307 | Canavan disease | 1 |
307. Canavan disease
Clinical trials : 6 / Drugs : 11 - (DrugBank : 5) / Drug target genes : 2 - Drug target pathways : 2
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05317780 (ClinicalTrials.gov) | February 10, 2020 | 24/3/2022 | Canavan-Single Patient IND | Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease | Canavan Disease | Drug: rAAV9-CB6-AspA | Barry J. Byrne | University of Miami;University of Massachusetts, Worcester | Available | 18 Months | 24 Months | Male | United States |